advertisement
11.4 Prostaglandins (40)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins25148 ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture
Osborne NN; Ji D; Abdul Majid AS; Fawcett RJ; Sparatore A; Del Soldato P
Investigative Ophthalmology and Visual Science 2010; 51: 284-294
25348 Stimulation of Prostaglandin EP2 Receptors on RGC-5 Cells in Culture Blunts the Negative Effect of Serum Withdrawal
Kang K D; Andrade da Costa B L S; Osborne N N
Neurochemical Research 2010; 1-10
25386 Inhibition and activation of carbonic anhydrase I and II activities by effective ocular hypotensive agents (timolol and latanoprost)
Hirose J; Hata T; Ono Y
Journal of Biological Inorganic Chemistry 2009; 14: S194-S195
25165 Experimental model of ocular hypertension in the rat: study of the optic nerve capillaries and action of hypotensive drugs
Díaz F; Villena A; Vidal L; Moreno M; García-Campos J; Pérez de Vargas I
Investigative Ophthalmology and Visual Science 2010; 51: 946-951
25457 Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
Ishikawa M; Yoshitomi T
Clinical Ophthalmology 2009; 3: 493-500
25447 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
Ishikawa S; Nakamura Y; Sakai H; Henzan I; Sawaguchi S
Clinical Ophthalmology 2009; 3: 395-400
25265 A Model-Based Meta-Analysis of the Effect of Latanoprost Chronotherapy on the Circadian Intraocular Pressure of Patients With Glaucoma or Ocular Hypertension
Luu K T; Raber S R; Nickens D J; Vicini P
Clinical Pharmacology and Therapeutics 2010; 87:421-425
25440 Latanoprost in pediatric glaucoma-pediatric exposure over a decade
Black A C; Jones S; Yanovitch T L; Enyedi L B; Stinnett S S; Freedman S F
Journal of AAPOS 2009; 13: 558-562
25423 Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients
Schlote T; Tzamalis A; Kynigopoulos M
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 459-462
25450 Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
Horsley M B; Kahook M Y
Clinical Ophthalmology 2009; 3: 291-295
25445 Bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension
Curran M P
Drugs and Aging 2009; 26: 1049-1071
25535 A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
Facio A C; Reis A S; Vidal K S; de Moraes C G; Suzuki R; Hatanaka M; Susanna R
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 447-451
25086 Efficacy and Tolerability of Bimatoprost versus Travoprost in Patients Previously on Latanoprost: a 3-Month, Randomized, Masked-Evaluator, Multicenter Study
Kammer J; Katzman B; Ackerman S; Hollander D
British Journal of Ophthalmology 2010; 94: 74-79
25424 Bilateral deepening of upper lid sulcus from topical bimatoprost therapy
Yam J C S; Yuen N S Y; Chan C W N
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 471-472
25174 Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost
Yamazaki S; Nanno M; Kimura T; Suzumura H; Yoshikawa K
Japanese Journal of Ophthalmology 2010; 54: 7-14
25418 Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma
Ergin A; Ornek K; Gullu R; Bulcun E; Ekici M; Ekici A
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 463-466
25533 Long-term effects of prostaglandin analogues on the anterior chamber depth of patients with primary open-angle glaucoma
Simek S; Yulek F; Cakmak H B; Midillioglu N K
Cutaneous and Ocular Toxicology 2009; 28: 125-128
25425 Intraocular pressure (IOP) reduction by latanoprost in japanese normal tension glaucoma patients over a five-year period stratified by presenting IOP
Tsuda M; Ando A; Matsuyama K; Otsuji T; Fukui C; Maenishi N; Kuwahara A; Nishimura T; Jo N; Nambu H
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 441-445
25465 A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
Godfrey D A; Peplinski L S; Stewart J A; Stewart W C
Clinical Ophthalmology 2009; 3: 189-194
25472 Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: A meta-analysis
Eyawo O; Nachega J; Lefebvre P; Meyer D; Rachlis B; Lee C -W; Kelly S; Mills E
Clinical Ophthalmology 2009; 3: 447-456
25593 Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study
Uusitalo H; Pillunat L E; Ropo A
Acta Ophthalmologica 2010; 88: 12-19
25478 Bimatoprost therapy in glaucoma
Calugaru D; Calugaru M
Oftalmologia 2009; 53: 34-45
25099 Do antiglaucomatous prostaglandins induce melanogenesis in human conjunctiva?: an impression cytology pilot study
Cagigrigoriu A; Boero E; Carenini AB; Rolle T; Cappia S; Bacillo E; Papotti M; Gregori D; Brovarone FV; Grignolo FM
Journal of Glaucoma 2010; 19: 44-50
25059 Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma
Konstas AG; Holló G; Mikropoulos D; Tsironi S; Haidich AB; Embeslidis T; Georgiadou I; Irkec M; Melamed S
British Journal of Ophthalmology 2010; 94: 209-213
25534 Extensive facial skin pigmentation after latanoprost treatment
Chien K -H; Lu D -W; Chen J -T
Cutaneous and Ocular Toxicology 2009; 28: 185-187
